智通财经APP获悉，诺和诺德(NVO.US)周五宣布，在一项后期试验中，该公司流行的肥胖治疗药物semaglutide(名为Wegovy)在7.2毫克的较高剂量下于72周内减重20 ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A high-dose form of Novo Nordisk’s obesity drug Wegovy, together with lifestyle intervention, led to greater ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side effects ...

announced that Ozempic and Wegovy are among 15 medications selected for Medicare price negotiations under the Inflation Reduction Act. The stock price decline extends the sell-off, with Novo ...